#1 Best Biotech Stock To Buy Now

  • Post category:Biotechnology
  • Reading time:3 mins read
Get Email Alerts and Follow Us:

In this article we look at the best biotech stock to buy now according to at least one major analyst.

Vir Biotechnology is a commercial-stage immunology company that creates therapeutic products for the treatment and avoidance of dangerous infectious diseases. It creates Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand, as well as VIR-2218, VIR-3434, and VIR-1111 for the treatment of hepatitis B virus, influenza A virus prevention with VIR-2482, and human immunodeficiency virus prevention with VIR-2482.

A collaboration and license agreement with Alnylam Pharmaceuticals, Inc., a grant agreement with the Bill and Melinda Gates Foundation, a license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited, and grant agreements with the National Institutes of Health are all in place for the business.

New data on the flu vaccine will be released by the company in the upcoming year, which could boost the biotech stock’s growth. The antibody therapy, known as VIR-2482, offers users comprehensive defense against flu strains that may last the duration of a flu season.

We anticipate that VIR-2482 (intramuscularly injected monoclonal antibody for prophylaxis/prevention of influenza A) data, which will be released in mid-2023, will demonstrate significantly better efficacy than currently approved and rival pipeline-stage flu vaccines. As a result, we anticipate that consensus estimates will be materially revised upward.


Frequently Asked Questions

When did Vir Biotechnology go public?

Vir Biotechnology went public in October 2019, pricing its initial offering at $20 per share.

Do any famous investors hold Vir Biotechnology Inc. stock?

Yes, Vir Biotechnology Inc. stock is held by several notable investors, including Bill Gates, Warren Buffett, and Vanguard Group.

Is Vir Biotechnology working on a flu vaccine that doesn’t need to guess which flu strain will be prevalent the next year?

Yes. VIR’s strategy of targeting a highly conserved (>98%) region of the flu virus hemagglutinin (HA) stem avoids having to predict which strains will be prevalent each flu season.
Get Email Alerts and Follow Us: